Financial Data and Key Metrics Changes - In Q4 2025, total company revenues grew 11% to a record $814 million, with adjusted EBITDA increasing by 13% and adjusted EPS rising by 75% [18][19] - For the full year 2025, total company revenue reached $3 billion, an 8% increase, with adjusted EBITDA growing 10% to $688 million and adjusted EPS rising 43% to $0.83 [21][20] - Operating cash flow for the full year was strong at $340 million, and net leverage was reduced to 3.5 times [18][21] Business Line Data and Key Metrics Changes - The affordable medicines segment was flat at $437 million in Q4, while specialty revenues surged 38% year-over-year to $167 million, driven by strong demand for key brands [19][20] - AvKARE revenues grew 24% to $211 million, benefiting from strong growth in the government channel [19] - For the full year, affordable medicines grew 4%, specialty grew 19%, and AvKARE grew 12% [21] Market Data and Key Metrics Changes - The specialty segment's growth was attributed to products like CREXONT, Rytary, and the new Brekiya auto-injector [19] - The company expects to launch 20-30 new products each year in the affordable medicines segment, with a focus on complex generics and injectables [11][12] Company Strategy and Development Direction - The company aims to become America's number one affordable medicines company, focusing on innovative therapies and expanding access to complex medicines [6][5] - A strategic focus on vertical integration in biosimilars is emphasized, with plans to build a strong commercial platform and manufacturing capabilities [7][14] - The company is also enhancing operational efficiency through digitization, automation, and AI [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing a strong foundation and multiple growth drivers, including new branded launches and a robust pipeline of affordable medicines [29][28] - The company anticipates continued growth in 2026, with guidance for revenue growth of 1%-4%, adjusted EBITDA growth of 5%-10%, and adjusted EPS growth of 12%-24% [22][23] Other Important Information - The company was recently added to the S&P SmallCap 600 index, enhancing visibility with the investment community [27] - The company is well-positioned to capitalize on the upcoming wave of biologics losing exclusivity, which presents significant long-term growth opportunities [8][14] Q&A Session Summary Question: Update on CREXONT market response and revenue targets for 2026 - Management reported a significant uptake with 80% of IR patients converting to CREXONT, aiming to double market share and reach 100,000 patients in 2026 [33][34] Question: Clarification on AvKARE's growth expectations - Management explained that while the distribution business is declining, the government channel remains strong, and gross margins have improved significantly [39][40] Question: Status of the Pfizer GLP-1 partnership - The collaboration is progressing well, with no immediate changes expected, and the company retains marketing rights for several countries [49][48] Question: Insights on the generic Omnipaque opportunity - Management acknowledged the complexity of the supply chain but expressed optimism about market entry and growth potential [58][60] Question: Discussion on Xolair and market competition - Management highlighted the limited competition expected in the Xolair market and the potential for significant revenue contributions starting in 2027 [59][60]

Financial Data and Key Metrics Changes - Revenue grew 8% in 2025, reaching $3 billion, with adjusted EBITDA increasing by 10% to $688 million and adjusted EPS rising by 43% to $0.83 [4][21][22] - Q4 revenues increased by 11% to a record $814 million, with adjusted EBITDA growing 13% and adjusted EPS soaring 75% [19][20] Business Segment Data and Key Metrics Changes - Affordable Medicines segment revenue was flat at $437 million, while Specialty revenues surged 38% to $167 million, driven by strong demand for key brands [20] - AvKARE revenues grew 24% to $211 million, benefiting from strong growth in the government channel [20] Market Data and Key Metrics Changes - The specialty segment, particularly CREXONT, achieved a market share of over 3% one year post-launch, with expectations to double revenue in 2026 [9][35] - The company anticipates a significant opportunity in biosimilars, with plans to have six products in the U.S. market by 2027 [6][14] Company Strategy and Development Direction - The company aims to become America's number one affordable medicines company, focusing on innovative therapies and expanding access to complex medicines [5] - Strategic growth opportunities include expanding the injectable segment and building a strong commercial platform for biosimilars [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong foundation and a robust pipeline of new product launches [4][30] - The company expects continued top and bottom line growth in 2026, with guidance indicating revenue growth of 1%-4% and adjusted EBITDA growth of 5%-10% [24][25] Other Important Information - The company successfully reduced net leverage from 7.4x in 2019 to 3.5x at the end of 2025, and refinanced its debt to lower interest expenses [22][23] - Amneal was added to the S&P SmallCap 600 index, enhancing visibility with the investment community [29] Q&A Session Summary Question: Update on CREXONT market response and revenue targets - Management noted a significant uptake with 80% of IR patients converting to CREXONT, aiming to double market share and reach 100,000 patients in 2026 [35][36] Question: Growth expectations for AvKARE - Management explained that while the distribution business is declining, the government channel remains strong, with gross margins improving significantly [40][41] Question: Status of the Pfizer GLP-1 partnership - The collaboration is progressing well, with no immediate changes expected, and the company retains marketing rights for 18 countries [49] Question: Generic Omnipaque opportunity and competition - Management acknowledged the complexity of the supply chain but expressed confidence in capturing market share, with plans to introduce additional strengths [56][59] Question: Xolair market potential - Management highlighted the limited competition in the Xolair market and expected strong sales through private label partnerships [58][59]